Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

Creative Commons License

Kohli P., Wallentin L., Reyes E., Horrow J., Husted S., Angiolillo D. J., ...More

CIRCULATION, vol.127, no.6, pp.673-681, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 127 Issue: 6
  • Publication Date: 2013
  • Doi Number: 10.1161/circulationaha.112.124248
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.673-681
  • Hacettepe University Affiliated: Yes


Background-We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (eg, cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events.